Show simple item record

dc.contributor.authorMarino, Katherine R.
dc.contributor.authorLundberg, Rachel L.
dc.contributor.authorJasrotia, Aastha
dc.contributor.authorMaranda, Louise S.
dc.contributor.authorThompson, Michael J.
dc.contributor.authorBarton, Bruce A.
dc.contributor.authorAlonso, Laura C.
dc.contributor.authorNwosu, Benjamin U.
dc.date2022-08-11T08:10:09.000
dc.date.accessioned2022-08-23T16:57:17Z
dc.date.available2022-08-23T16:57:17Z
dc.date.issued2017-02-09
dc.date.submitted2017-02-10
dc.identifier.doi10.13028/M2G59M
dc.identifier.urihttp://hdl.handle.net/20.500.14038/43106
dc.description<p>The explanation for codes used in this dataset is available under "Additional Files." Data collection dates: January 1, 2006 - September 30, 2015.</p>
dc.description<p>Methodology is documented in manuscript.</p>
dc.description.abstractManuscript abstract: IMPORTANCE: >50% of patients with new-onset type 1 diabetes (T1D) do not enter partial clinical remission (PCR); early identification of these patients may improve initial glycemic control and reduce long-term complications. AIM: To determine whether routinely obtainable clinical parameters predict non-remission in children and adolescents with new-onset T1D. SUBJECTS AND METHODS: Data on remission were collected for the first 36 months of disease in 204 subjects of ages 2-14 years with new-onset type 1 diabetes. There were 86 remitters (age 9.1±3.0y; male 57%), and 118 non-remitters (age 7.0±3.1y; male 40.7%). PCR was defined as insulin-dose adjusted hemoglobin A1c of ≤9. RESULTS: Non-remission occurred in 57.8% of subjects. Univariable analysis showed that the risk for non-remission was increased 9-fold in patients with 4 diabetes-associated auto-antibodies (OR = 9.90, p = 0.010); 5-fold in patients(odds ratio = 5.38, p = 0.032), 3-fold in those with bicarbonate of/dL at diagnosis (OR = 3.71, p = 0.008). Combined estimates of risk potential for HC03 and the number of autoantibodies by multivariable analysis, adjusted for BMI standard deviation score, showed HC03/dL with a clinically significant 10-fold risk (OR = 10.1, p = 0.074); and the number of autoantibodies with a 2-fold risk for non-remission (OR = 1.9, p = 0.105). Male sex and older age were associated with decreased risk for non-remission. A receiver-operating characteristic curve model depicting sensitivity by 1-specificity for non-remission as predicted by bicarbonate/dL, age3 diabetes-associated autoantibodies had an area under the curve of 0.73. CONCLUSIONS: More than 50% of children and adolescents with new-onset T1D do not undergo partial clinical remission and are thus at an increased risk for long-term complications of diabetes mellitus. A predictive model comprising of bicarbonate/dL, age3 diabetes-associated autoantibodies has 73% power for correctly predicting non-remission in children and adolescents with new-onset T1D. Early identification of these non-remitters may guide the institution of targeted therapy to limit dysglycemia and reduce the prevalence of long-term deleterious complications.
dc.description.sponsorshipThe authors received no specific funding for this work.
dc.format.medium.xlsx (107 KB)
dc.language.isoen_US
dc.publishereScholarship@UMMS
dc.relation<p>This dataset is the primary data source for the following published study: Marino KR, Lundberg RL, Jasrotia A, Maranda LS, Thompson MJ, Barton BA, Alonso LC, Nwosu BU. <a href="http://escholarship.umassmed.edu/peds_endocrinology/61/">A predictive model for lack of partial clinical remission in new-onset pediatric type 1 diabetes</a>. PLoS One. 2017 May 1;12(5):e0176860. doi:10.1371/journal.pone.0176860. eCollection 2017. PubMed PMID: 28459844.</p>
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectnew-onset type 1 diabetes
dc.subjectT1D
dc.subjectremission
dc.subjectchildren
dc.subjectadolescent
dc.subjectEndocrine System Diseases
dc.subjectEndocrinology, Diabetes, and Metabolism
dc.subjectNutritional and Metabolic Diseases
dc.subjectPediatrics
dc.titleData from: A Predictive Model for Lack of Partial Clinical Remission in New-onset Pediatric Type 1 Diabetes
dc.typeDataset
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/pediatrics_data/5
dc.identifier.contextkey9666127
dc.file.descriptionDataset in csv format
dc.file.descriptionNwosu T1D Remission Dataset Code List
refterms.dateFOA2022-08-29T15:58:51Z
html.description.abstract<p>Manuscript abstract:</p> <p>IMPORTANCE: >50% of patients with new-onset type 1 diabetes (T1D) do not enter partial clinical remission (PCR); early identification of these patients may improve initial glycemic control and reduce long-term complications.</p> <p>AIM: To determine whether routinely obtainable clinical parameters predict non-remission in children and adolescents with new-onset T1D.</p> <p>SUBJECTS AND METHODS: Data on remission were collected for the first 36 months of disease in 204 subjects of ages 2-14 years with new-onset type 1 diabetes. There were 86 remitters (age 9.1±3.0y; male 57%), and 118 non-remitters (age 7.0±3.1y; male 40.7%). PCR was defined as insulin-dose adjusted hemoglobin A1c of ≤9.</p> <p>RESULTS: Non-remission occurred in 57.8% of subjects. Univariable analysis showed that the risk for non-remission was increased 9-fold in patients with 4 diabetes-associated auto-antibodies (OR = 9.90, p = 0.010); 5-fold in patients(odds ratio = 5.38, p = 0.032), 3-fold in those with bicarbonate of/dL at diagnosis (OR = 3.71, p = 0.008). Combined estimates of risk potential for HC03 and the number of autoantibodies by multivariable analysis, adjusted for BMI standard deviation score, showed HC03/dL with a clinically significant 10-fold risk (OR = 10.1, p = 0.074); and the number of autoantibodies with a 2-fold risk for non-remission (OR = 1.9, p = 0.105). Male sex and older age were associated with decreased risk for non-remission. A receiver-operating characteristic curve model depicting sensitivity by 1-specificity for non-remission as predicted by bicarbonate/dL, age3 diabetes-associated autoantibodies had an area under the curve of 0.73.</p> <p>CONCLUSIONS: More than 50% of children and adolescents with new-onset T1D do not undergo partial clinical remission and are thus at an increased risk for long-term complications of diabetes mellitus. A predictive model comprising of bicarbonate/dL, age3 diabetes-associated autoantibodies has 73% power for correctly predicting non-remission in children and adolescents with new-onset T1D. Early identification of these non-remitters may guide the institution of targeted therapy to limit dysglycemia and reduce the prevalence of long-term deleterious complications.</p>
dc.identifier.submissionpathpediatrics_data/5
dc.contributor.departmentUMass Metabolic Network
dc.contributor.departmentDiabetes Division, Department of Medicine
dc.contributor.departmentDepartment of Quantitative Health Sciences
dc.contributor.departmentDivision of Endocrinology, Department of Pediatrics


Files in this item

Thumbnail
Name:
1-Nwosu_T1D_Remission_2017_02_ ...
Size:
55.14Kb
Format:
PDF
Thumbnail
Name:
Nwosu_T1D_Remission_2017_02_09.xlsx
Size:
117.4Kb
Format:
Microsoft Excel 2007

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/